101 related articles for article (PubMed ID: 26480922)
41. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Soysal T; Eskazan AE; Ar MC
Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
[TBL] [Abstract][Full Text] [Related]
42. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
43. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
44. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
45. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
46. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
[TBL] [Abstract][Full Text] [Related]
47. Response-related predictors of survival in CML.
Hanfstein B; Müller MC; Hochhaus A
Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
[TBL] [Abstract][Full Text] [Related]
48. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
49. Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Visser O; Cornelissen JJ; Westerweel PE
Haematologica; 2017 Nov; 102(11):1842-1849. PubMed ID: 28860339
[TBL] [Abstract][Full Text] [Related]
50. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
[TBL] [Abstract][Full Text] [Related]
51. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
52. CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Burin SM; Ghisla S; Ouchida AT; Aissa AF; Coelho MG; Costa TR; Marsola AP; Pinto-Simões B; Antunes LM; Curti C; Sampaio SV; de Castro FA
Int J Biol Macromol; 2016 May; 86():309-20. PubMed ID: 26812110
[TBL] [Abstract][Full Text] [Related]
53. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
54. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
55. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
56. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
57. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
Eskazan AE; Ozmen D
Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
[No Abstract] [Full Text] [Related]
58. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.
Menzin J; Lang K; Earle CC; Glendenning A
Drugs Aging; 2004; 21(11):737-46. PubMed ID: 15323579
[TBL] [Abstract][Full Text] [Related]
59. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
60. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
